Title: Randomized double blind control study of aripiprazole and risperidone on the treatment of schizophrenia
Abstract: Objective: To assess the efficacy and safety of aripiprazole on the treatment of schizophrenia. Method:A randomized,double-blind,double-dummy,comparative study was performed with a course of 6 weeks.Fifty-two Patients with schizophrenia were randomized into aripiprazole group(n=26) and risperidone group(n=26).The positive and negative syndrome scale(PANSS),clinical global impression(CGI),treatment emergent symptom scale(TESS) were used to asess the effectiveness and the safety of the treatment. Results:By the end of the 6 week treatment,In both groups,the scores of PANSS decreased significantly comparing to the baseline(P0.05) without statistically different between two groups.By the end of week 6,total clinical effective rates were 58.3% in aripiprazole group and 75% in risperidone group,without any statistically significant difference between the two groups.No severe adverse events were reported in both group.However,the influence on serum prolactin in aripiprazole group was much lower than in risperidone group. Conclusion: Aripiprazole has similar efficacy to risperidone in the antipsychotic treatment with mild impact on prolactin level.So aripiprazole is a safe and effective antipsychotics.
Publication Year: 2010
Publication Date: 2010-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot